A generous buyout offer has given investors something to cheer about.
The world's largest manufacturer of prescription drugs has officially entered the medical marijuana industry.
How much longer can they keep it up?
Despite missing revenue expectations, Aurora Cannabis laid out some encouraging numbers you may have missed.
The company's long R&D Day presentation gave investors reasons for optimism.
Here's what a benign briefing document means, and what it doesn't.
The company's peanut allergen desensitization therapy took an indirect step forward.
Lackluster sales of Nuplazid could finally take flight next year.
Investors better get ready for a busy week ahead.
Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
The company has some bold predictions for the year ahead that could make investors very rich.
A detailed look at a big clinical trial did not disappoint.
Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.
Investors worried about a couple of insider trades put pressure on the stock price.
Can their share prices continue to climb?
One of biotech's longest-running buyout rumors is picking up steam again.
Here's what bargain biotech shoppers need to know about Sarepta's future.
An executive's departure at a sensitive time has investors nervous.
Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?